BERLIN (AP)
— The German manufacturer of a notorious drug that caused thousands of babies
to be born with shortened arms and legs, or no limbs at all, issued its first
ever apology Friday — 50 years after pulling the drug off the market.
Gruenenthal
Group's chief executive said the company wanted to apologize to mothers who
took the drug during the 1950s and 1960s and to their children who suffered
congenital birth defects as a result.
"We
ask for forgiveness that for nearly 50 years we didn't find a way of reaching
out to you from human being to human being," Harald Stock said. "We
ask that you regard our long silence as a sign of the shock that your fate
caused in us."
Stock spoke
in the west German city of Stolberg, where the company is based, during the
unveiling of a bronze statue symbolizing a child born without limbs because of
thalidomide. The statue is called "the sick child" — a name German
victims group object to since all the victims are now adults. In German, the
name also implies cure.
The drug is
a powerful sedative and was sold under the brand name Contergan in Germany. It
was given to pregnant women mostly to combat morning sickness, but led to a
wave of birth defects in Europe, Australia, Canada and Japan. Thalidomide was
yanked from the market in 1961 and was also found to cause defects in the eyes,
ears, heart, genitals and internal organs of developing babies.
Thalidomide
was never approved for use in pregnant women in the United States.
Freddie
Astbury, of Liverpool, England, was born without arms or legs after his mother
took thalidomide. The 52-year-old said the apology was years long overdue.
"It's
a disgrace that it's taken them 50 years to apologize," said Astbury, of
the Thalidomide U.K. agency, an advocacy group for survivors. "I'm
gobsmacked (astounded)," he said. "For years, (Gruenenthal) have
insisted they never did anything wrong and refused to talk to us."
Astbury
said the drug maker should apologize not just to the people affected, but to
their families. He also said the company should offer compensation. "It's
time to put their money where their mouth is," he said. "For me to
drive costs about 50,000 pounds ($79,000) for a car with all the
adaptations," he said. "A lot of us depend on specialist care and
that runs into the millions."
Astbury
said he and other U.K. survivors have received some money over the years from a
trust set up by thalidomide's British distributor but that Gruenenthal has
never agreed to settle.
"We
invite them to sit around the table with us to see how far their apology will
go," he said. "I don't think they've ever realized the impact they've
had on peoples' lives."
Gruenenthal
settled a lawsuit in Germany in 1972 — 11 years after stopping sales of the
drug — and voiced its regret to the victims. But for decades, the company
refused to admit liability, saying it had conducted all necessary clinical
trial required at the time.
Stock
reiterated that position Friday, insisting that "the suffering that
occurred with Contergan 50 years ago happened in a world that is completely
different from today" and the pharmaceutical industry had learned a
valuable lesson from the incident.
"When
it developed Contergan Gruenenthal acted on the basis of the available
scientific knowledge at the time and met all the industry standards for the
testing of new drugs that were known in the 1950s and 1960s," he said.
A German
victims group rejected the company's apology as too little, too late.
"The
apology as such doesn't help us deal with our everyday life," said Ilonka
Stebritz, a spokeswoman for the Association of Contergan Victims. "What we
need are other things."
Stebritz
said that the 1970 settlement in Germany led to the creation of a €150 million
fund for some 3,000 German victims, but that with a normal life expectancy of
85 years the money wasn't enough. In many other countries, victims are still
waiting for compensation from Gruenenthal or its local distributors.
In July, an
Australian woman born without arms and legs after her mother took thalidomide
reached a multimillion dollar settlement with the drug's British distributor.
Gruenenthal refused to settle. The lawsuit was part of a class action and more
than 100 other survivors expect to have their claims heard in the next year.
Thalidomide
is still sold today, but as a treatment for multiple myeloma, a bone marrow
cancer and leprosy. It is also being studied to see if it might be useful for
other conditions including AIDS, arthritis and other cancers.
Maria Cheng
reported from London.
Related Articles:
Thalidomide victims say drug company's apology is an insult
Gruenenthal's thalidomide apology 'insulting'
Thalidomide victims say drug company's apology is an insult
Gruenenthal's thalidomide apology 'insulting'